Largos supervivientes y terapias dirigidas en melanoma avanzado - page 42

1ª L

•

BRAF

V600 mutado

• ECOG PS 0-1

N = 300

Dabrafenib

Trametinib

Ipilimumab

Nivolumab

Ipilimumab

Nivolumab

Dabrafenib

Trametinib

Prog

Objetivos

Primario: supervivencia global

ECOG-ACRIN

EA16134

: fase III

(NCT02224781)

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,32,33,34,35,36,37,38,39,40,41 43,44,45,46